

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claim 1 (Currently amended): A non-toxic *Pseudomonas* exotoxin A-like (“PE-like”) chimeric immunogen comprising in sequence: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor of a cell from a mammal; (2) a translocation domain comprising an amino acid sequence at least ~~60%~~ 90% identical to the sequence of *Pseudomonas* exotoxin A (PE) (SEQ ID NO:2) ~~PE domain II from amino acid position 280 to amino acid position 344 thereof and wherein the domain is capable of effecting translocation to a the cell-cytosol of the cell~~; (3) ~~an amino acid sequence encoding an endoplasmic reticulum (“ER”) retention domain that comprises an ER retention sequence~~; (4) an epitope presenting domain ~~located at the PE-Ib domain location of PE~~ and having one cysteine to cysteine disulfide bonded loop and comprising an amino acid sequence of between 5 and 350 amino acids that encodes an epitope that is non-native to PE domain Ib and is located within the loop, and wherein the epitope is from a pathogen; and (4) an endoplasmic reticulum (ER) retention domain wherein the ER domain is capable of effecting translocation to the endoplasmic reticulum of the cell and wherein the ER retention domain lacks ADP ribosylation activity.

Claim 2 (Currently Amended): The immunogen of claim 1, wherein the cell recognition domain is domain 1a of PE, the translocation domain is domain II of PE, and the ER retention domain is domain III of PE, ~~wherein domain III lacks ADP ribosylation activity.~~

Claim 3 (previously presented): The immunogen of claim 1 wherein the cell recognition domain is domain Ia of PE.

Claim 7 (previously presented): The immunogen of claim 1 wherein the translocation domain comprises the amino acid sequence of SEQ ID NO:2. from the amino acid at position to 280 to the amino acid at position 364.

Claim 8 (previously presented): The immunogen of claim 1 wherein the translocation domain is domain II of PE.

Claim 12 (currently amended): The immunogen of claim 1 wherein the ER retention domain is domain III of PE having a deletion which eliminates ~~, wherein domain III~~ lacks ADP ribosylation activity.

Claim 13 (previously presented): The immunogen of claim 1 wherein the ER retention sequence comprises REDLK (SEQ ID NO:11).

Claim 14 (new): The immunogen of claim 1, wherein the translocation domain comprises an amino acid sequence at least 95% identical to the PE amino acid sequence (SEQ ID NO:2) from amino acid position 280 to amino acid position 344 thereof.

Claim 15 (new): The immunogen of claim 15, wherein the translocation domain comprises an amino acid sequence at least 98% identical to the PE amino acid sequence (SEQ ID NO:2) from amino acid position 280 to amino acid position 344 thereof.

Claim 16 (new): The immunogen of claim 1, wherein the translocation domain comprises an amino acid sequence identical to the PE amino acid sequence (SEQ ID NO:2) from amino acid position 280 to amino acid position 344 thereof.

Claim 17 (new): The immunogen of claim 1, wherein the cell is from a rodent or rabbit.

Claim 18 (new): The immunogen of claim 1, wherein the cell is from a primate or a human.